Use of Kv11.1 channel inhibitors for treatment of pulmonary hypertension
Provided are methods of treating pulmonary artery hypertension with a Kv11.1 (ERG or hERG1) channel inhibitor. In certain embodiments, the Kv11.1 channel inhibitor is dofetilide. In certain embodiments, a subject to be treated using a method of the disclosure is not in need of treatment for an irregular heart rhythm, e.g., atrial fibrillation.
1. A method of treating pulmonary artery hypertension, comprising administering to a subject in need thereof an effective amount of a Kv11.1 channel inhibitor, wherein the Kv11.1 inhibitor is selected from the group consisting of dofetilide, haloperidol, terfenadine, astemizole, cisapride, and amiodarone.
2. The method of claim 1 , wherein the pulmonary artery hypertension is not associated with chronic obstructive pulmonary disease (COPD).
3. The method of claim 1 , wherein the pulmonary artery hypertension is associated with chronic obstructive pulmonary disease (COPD).
4. The method of claim 1 , wherein the subject is not in need of treatment for irregular heart rhythm.
5. The method of claim 4 , wherein the subject is not in need of treatment for atrial fibrillation.
6. The method of claim 1 , wherein the subject is a human.
7. The method of claim 1 , wherein the Kv11.1 inhibitor is dofetilide.
8. The method of claim 1 , wherein the Kv11.1 inhibitor is administered orally.
9. The method of claim 1 , wherein the Kv11.1 inhibitor is administered parenterally.
10. The method of claim 9 , wherein the Kv11.1 inhibitor is administered intravenously or intraperitoneally.
11. The method of claim 1 , wherein the Kv11.1 inhibitor is administered directly to lungs.
12. The method of claim 11 , wherein the Kv11.1 inhibitor is administered intratracheally or by inhalation.